Browsing Tag
Recordati S.p.A.
3 posts
Zanvastro approval validates Ionis Pharmaceuticals neurology strategy, but how large is the market?
Ionis Pharmaceuticals has secured the first FDA approval for Alexander disease with Zanvastro, a quarterly RNA-targeted treatment priced at $285,000 per dose, while the ultra-rare population limits its standalone commercial ceiling.
Can CVC and Groupe Bruxelles Lambert’s Recordati bid reshape Italian pharma consolidation?
CVC and Groupe Bruxelles Lambert want Recordati private. Find out why the €10.7B bid could reshape Italian pharma consolidation.
What Galderma Group AG’s new CFO appointment reveals about its next phase as a global dermatology company
Galderma Group AG appoints a new CFO as it enters its post-IPO phase. Find out what the leadership change signals for investors and strategy.